Naslov
Complications of suprahepatic inferior caval vein obstruction in rats. Pentadecapeptide BPC 157 induces inferior-superior caval vein shunt through azygos vein and counteracts venous thrombosis and arrhythmias

Autori
Gojković, Slaven ; Krezić, Ivan ; Žižek, Helena ; Malekinušić, Dominik ; Đurašin, Tajana ; Drmić, Domagoj ; Horvat, Katarina ; Seiwerth, Sven ; Sikirić, Predrag

Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni

Skup
Digestive Disease Week

Mjesto i datum
San Diego (CA), Sjedinjene Američke Države, 18.05.2019. - 21.05.2019

Vrsta sudjelovanja
Poster

Vrsta recenzije
Međunarodna recenzija

Ključne riječi
BPC 157 ; inferior caval vein ; thrombosis ; arrhythmias

Sažetak
Aim. Pentadecapeptide BPC 157 therapy in suprahepatic inferior caval vein (ICV) obstruction, mimicking Budd Chiari syndrome in rats, 15 min, 24 h, 48 h. The counteraction of the suprahepatic inferior caval vein (ICV) obstruction (rapid cloth formation in the portal vein (PV), superior mesenteric vein (SMV), lienal vein (LV), ICV, peaked P waves, significant ST-elevation, and tachycardia ; rapid bypassing shunt ICV-superior caval vein (SCV). Previously, in rats with portal triad obstruction, BPC 157 counteracted portal hypertension and caval hypotension (Gastroenterology 2017, Vol. 152, Issue 5, S909–S910 ; 2015, Vol. 148, Issue 4, S-650 ; 2015, Vol. 148, Issue 4, S-548), ICV-hypertension and aortal hypotension in rats with infrarenal ICV-occlusion (Vascul Pharmacol 2018 ; 106:54-66) as well as portal and caval hypertension in rats with short-lasting suprahepatic occlusion of ICV (Gastroenterology, Volume 154, Issue 6, Supplement 1, S-532). Also, BPC 157 prevents and reverses venous (Vascul Pharmacol 2018 ; 106:54-66) and arterial thrombosis (J Physiol Pharmacol 2009 ; 60 Suppl 7:161-5). Methods: Medication (BPC 157 (10 μg/kg, 10 ng/kg), or saline (5 ml/kg) (controls)) was applied as an abdominal bath immediately after suprahepatic ICV obstruction. Results: Suprahepatic ICV obstruction regularly produced considerable thrombosis at 15 min (0.0138±0.001 ICV, 0.004±0.0009 PV, 0.0032±0.0009 SMV, 0.0025±0.0008 LV) ; 24 h (0.0121±0.001 ICV, 0.0117±0.0009 PV, 0.0126±0.0009 SMV, 0.0041±0.0008 LV) ; 48 h (0.0064±0.001 ICV, 0.0068±0.0009 PV, 0.0133±0.0009 SMV, 0.0007±0.0008 LV). Contrarily, in BPC 157 treated rats, the weights of the formed clots were considerably smaller: 10 μg/kg: at 15 min (0.0064±0.0008 ICV, 0.0015±0.00008 PV, 0.0009±0.00007 SMV, 0.0011±0.0008 LV) ; 24 h (0.00391±0.0009 ICV, 0.0056±0.00009 PV, 0.0070±0.0009 SMV, 0.0007±0.00008 LV) ; 48 h (0.0044±0.001 ICV, 0.0025±0.0009 PV, 0.0068±0.0009 SMV, 0.0007±0.0008 LV) (*P≤0.05, at least vs. control). A similar beneficial effect was obtained with the lower BPC 157 dosage. Rats with suprahepatic ICV obstruction immediately exhibited peaked P waves, significant ST- elevation, and tachycardia an effect persisting till the end of the experiment. The peaked P waves, ST- elevation and tachycardia were completely absent in all BPC 157-treated rats (Fisher exact probability test P≤0.05 at least vs. control). As a conclusive point, ICV venography demonstrated a rapid bypassing through the azygos vein along with administration of the abdominal bath of BPC 157 (Fig. 1 ICV venography presentation as described (Vascul Pharmacol 2018 ; 106:54-66), left control, right BPC 157). Conclusion. BPC 157 therapy, with a rapid bypassing pathway between the ICV and SCV through the azygos vein, counteracted the course of the thrombosis in all veins, and ECG acute right ventricular overload

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti, Biotehnologija u biomedicini (prirodno područje, biomedicina i zdravstvo, biotehničko područje)

POVEZANOST RADA